

s/Julie Agozino/
Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
LYN HOWARD JONES, et al

Group Art Unit: 1614

Serial No.: 10/599,707

Examiner: Not Yet Assigned

Confirmation No.: 3037

Filed: October 5, 2006

**For: SULFER-LINKED IMIDAZOLE
COMPOUNDS FOR THE TREATMENT OF
HIV**

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 16-1445.

- ☒ Applicant requests that the Examiner consider the following copending applications:

| Application Serial No. | Filing Date | Docket No. |
|------------------------|-------------|------------|
| 10/657,033 | 09-05-2003 | PC25402A |
| | | |
| | | |

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☒ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

Derwent Abstracts enclosed for foreign language applications WO 02/42279, O00/06569, WO 98/16507, WO 00/21954, WO 02/42300, WO 02/42302, WO 02/42301, DE 198 34 047 A, WO 00/06567, AND WO 8/23919.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 16-1445. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: February 21, 2007

/Jeffrey H. Tidwell/
Jeffrey H. Tidwell
Attorney for Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233